Rajesh Kumar
Stock Analyst at HSBC
(3.01)
# 1,488
Out of 5,017 analysts
26
Total ratings
58.82%
Success rate
9.65%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $203.77 | +15.33% | 2 | Oct 9, 2025 | |
| NVO Novo Nordisk | Upgrades: Buy | $70 | $57.50 | +21.74% | 2 | Oct 2, 2025 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $230.30 | - | 4 | Oct 1, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Hold | $675 → $700 | $819.40 | -14.57% | 3 | Aug 27, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $26.42 | +58.97% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $524.58 | +27.72% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $205.14 | +36.49% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $358.66 | +28.26% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $20.02 | -35.06% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $43.54 | +21.73% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $26.74 | +262.75% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $102.30 | +21.21% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.73 | +102.18% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $85.70 | +43.52% | 1 | Jul 14, 2023 |
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $203.77
Upside: +15.33%
Novo Nordisk
Oct 2, 2025
Upgrades: Buy
Price Target: $70
Current: $57.50
Upside: +21.74%
AbbVie
Oct 1, 2025
Downgrades: Hold
Price Target: n/a
Current: $230.30
Upside: -
Eli Lilly and Company
Aug 27, 2025
Upgrades: Hold
Price Target: $675 → $700
Current: $819.40
Upside: -14.57%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $26.42
Upside: +58.97%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $524.58
Upside: +27.72%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $205.14
Upside: +36.49%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $358.66
Upside: +28.26%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $20.02
Upside: -35.06%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $43.54
Upside: +21.73%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $26.74
Upside: +262.75%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $102.30
Upside: +21.21%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $24.73
Upside: +102.18%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $85.70
Upside: +43.52%